Post on 02-Feb-2023
Defining the role ofGLP-1 receptor agonists forindividualized treatment oftype 2 diabetesExpert Rev. Endocrinol. Metab. Early online, 1–12 (2014)
Daisuke Yabe*1–3
and Yutaka Seino1
1Center for Diabetes, Endocrinology
and Metabolism, Kansai Electric Power
Hospital, Osaka, Japan2Center for Metabolism and Clinical
Nutrition, Kansai Electric Power
Hospital, Osaka, Japan3Division of Molecular and Metabolic
Medicine, Kobe University Graduate
School of Medicine, Kobe, Japan
*Author for correspondence:
Tel.: +81 664 585 821
Fax: +81 664 586 994
ydaisuke-kyoto@umin.ac.jp
With the advent of dipeptidyl peptidase (DPP)-4 inhibitors and glucagon-like peptide-1 receptoragonists (GLP-1 RAs) over the past decade, incretin therapy has become established as animportant treatment strategy for type 2 diabetes mellitus (T2DM), with an efficacy and safetyprofile distinct from that of other anti-hyperglycemic agents. However, our understanding ofthe optimal clinical use of incretins remains incomplete. This review focuses on the use ofGLP-1 RAs in the treatment of T2DM, with reference to the differing dominant mechanismsof action between short- and long-acting GLP-1 RAs and the clinical implications of thisdifference. The role of GLP-1 and the effects of GLP-1 RAs in various organs other than thepancreas will also be discussed.
KEYWORDS: albiglutide • DPP-4 inhibitor • dulaglutide • exenatide • exenatide LAR • GLP-1 receptor agonist • incretin
• liraglutide • lixisenatide • type 2 diabetes
Type 2 diabetes mellitus (T2DM) is a progres-sive metabolic disorder characterized by deteri-oration of pancreatic b-cell function andinsulin resistance in the liver and peripheraltissues. These factors combine and result inoverproduction of hepatic blood glucose andelevations in plasma glucose (FPG) in the fast-ing state, and insufficient glucose uptake bymuscle cells and elevated postprandial plasmaglucose (PPG) following a meal [1]. In additionto the b-cell, liver and muscle, dysfunction ofthe pancreatic a-cell (hyperglucagonemia), thefat cell (accelerated lipolysis), kidney (increasedglucose reabsorption), brain (insulin resistance)and gastrointestinal tract (incretin system) canall play an important role in the developmentand progression of T2DM [1].
The incretin system consists of two gut hor-mones, glucose-dependent insulinotropic poly-peptide and glucagon-like peptide-1 (GLP-1),which are released by gastrointestinal endocrinecells following food intake to stimulate insulinsecretion from b-cells glucose dependently [2,3].GLP-1 is also associated with suppression ofglucagon secretion from a-cells and a delayingeffect of gastric emptying that reduces therate of glucose absorption from the small
intestine [4], and has an inhibitory neurologicalinfluence on appetite and glucose ingestion[2,3,5–7]. Together, the incretin effects in responseto glucose intake ensure that PPG excursionsare limited, regardless of carbohydrate loadfrom a meal [8].
Patients with T2DM demonstrate animpaired capability to regulate their incretineffect, which may contribute to the exagger-ated PPG excursions [9]. Efforts to correct thisdysfunction with exogenous GLP-1 have beenhampered by the short half-life of the peptidein the body [10]. Human GLP-1 is rapidly bro-ken down by the DPP-4 enzyme and metabo-lized in the liver in a matter of minutes, withonly a small percentage of the intact hormonecirculating systemically [11]. The advent ofDPP-4 inhibitors and GLP-1 receptor agonists(GLP-1 RAs) over the past decade has seenincretin therapy become established as animportant treatment strategy for T2DM, withan efficacy and safety profile distinct fromother anti-diabetic agents [12,13]. However, ourunderstanding of the optimal clinical use ofincretins remains incomplete. This review willfocus on the GLP-1 RAs and their use in thetreatment of T2DM, with reference to the
informahealthcare.com 10.1586/17446651.2014.949672 � 2014 Informa UK Ltd ISSN 1744-6651 1
Review
Exp
ert R
evie
w o
f E
ndoc
rino
logy
& M
etab
olis
m D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y 18
2.24
9.24
7.14
on
09/0
3/14
For
pers
onal
use
onl
y.
differing dominant mechanisms of action between GLP-1 RAs.The role played by GLP-1 and the effects of GLP-1 RAs invarious organs other than the pancreas will also be discussed.
Classification & comparison of GLP-1 RAs in bothclinical & basic researchThere are currently five different GLP-1 RAs approved for usein patients with poorly controlled T2DM (TABLE 1). From a clin-ical perspective, these five agents can be divided into two broadcategories according to their relative half-lives: twice-daily exe-natide and once-daily lixisenatide are short-acting GLP-1 RAs,while once-daily liraglutide, once-weekly exenatide long-actingrelease (LAR) and albiglutide are long-acting GLP-1 RAs. Thedifference in the half-lives of these two classes appears to affectthe mechanistic action by which they exert their glucose-lowering effects. Short-acting GLP-1 RAs have limited effectson insulin secretion but strongly inhibit postprandial glucagonsecretion [14], which may aid PPG control [15]. They also have adelaying effect on gastric emptying, which results in pro-nounced reductions in PPG levels by reducing the rate of glu-cose absorption from the small intestine [5,16,17]. In contrast,long-acting GLP-1 RAs have a limited gastric emptying effect,and a consequently more modest effect on PPG excur-sions [18,19]. Instead, long-acting GLP-1 RAs provide reductionsin both FPG and PPG through stimulation of insulin secretionand inhibition of glucagon secretion [20].
Short-acting GLP-1 RAs
The first GLP-1 RA to be developed was exenatide, a syntheticversion of the 39-residue exendin-4 peptide originally isolatedfrom Gila monster lizard salivary secretions [21]. Exendin-4shares approximately 50% sequence homology with mammalianGLP-1 and is a potent agonist of the GLP-1 receptor [22]. Cru-cially, however, exendin-4 is resistant to proteolytic cleavage bythe DPP-4 enzyme, and so has a half-life of approximately 2.5 hin plasma, making it clinically viable for therapeutic use [21].Exenatide 10 mg is administered twice daily (b.i.d.) within60 min prior to the breakfast and evening meal [23,24]. In the piv-otal clinical studies of exenatide, glycated hemoglobin (HbA1c)levels were reduced by 0.8–0.9% over a period of 30 weeks,with relatively modest reductions in FPG (-0.6 mmol/l[-10.1 mg/dl]) indicating that the predominant glucose-loweringeffect was via reductions in PPG levels [25–27]. Blood glucosemeasurements confirmed that exenatide provides significantreductions in PPG after breakfast and after the evening meal [28].
The structure of the once-daily short-acting GLP-1 RA lixi-senatide is also based on the exendin-4 peptide, with modifica-tions to the C-terminal end. The binding affinity oflixisenatide for the human GLP-1 receptor is approximatelyfourfold greater than that of human GLP-1 in vitro [29,30].Like exenatide, the structure of lixisenatide is resistantto DPP-4 metabolism, and it has a half-life in plasma of2–4 h [20,31]. A dose-ranging study comparing once- versustwice-daily lixisenatide administration showed comparablereductions in HbA1c over 13 weeks, with a dose of 20 mg once
daily (q.d.) selected for Phase III studies on the basis that itprovided the best tolerability profile while conferring glycemiccontrol [32]. In the Phase III clinical study program, addition oflixisenatide to existing oral therapy resulted in significant reduc-tion in HbA1c of 0.7–0.9% over 24 weeks [33–36]. As with exe-natide, reductions in FPG were modest, although statisticallysignificant; however, reductions in PPG of 4.5–6.2 mmol/l(82–113 mg/dl) were much more marked [37]. Although thelargest reductions in PPG are generally seen post-breakfast, anunsurprising observation given the half-life of lixisenatide andit’s usual timing of administration, a pharmacologic study ofonce-daily lixisenatide administered before breakfast revealed asignificant reduction in PPG versus placebo after breakfast(p < 0.0001), lunch (p < 0.001) and dinner (p < 0.05) [16],demonstrating a significant effect on plasma glucose levelsthroughout the day. Furthermore, the effect of lixisenatide onPPG was correlated with a reduction in the rate of gastric emp-tying [16]. A recent study demonstrated that lixisenatide wasequally effective and well tolerated when administered q.d.before the main meal of the day versus before-breakfastadministration [38].
A head-to-head study of once-daily lixisenatide versus twice-daily exenatide showed statistically non-inferior reductions inHbA1c over 24 weeks (-0.8 vs -1.0%; treatment difference0.17% [95% CI: 0.033–0.297]) despite the different dosingregimens [36]. Although PPG levels were not recorded in thisstudy, both lixisenatide and exenatide showed moderate reduc-tions in FPG (-1.22 vs -1.45 mmol/l [-22 vs -26.1 mg/dl]), inline with the predominant PPG-lowering effects associated withshort-acting GLP-1 RAs.
Long-acting GLP-1 RAs
A LAR formulation of exenatide was subsequently developed toprovide consistent availability in plasma with once-weekly dos-ing. The LAR formulation consists of injectable microspheres ofexenatide and a biodegradable polymer that provides sustainedexenatide release into plasma with a half-life of approximately2 weeks [39]. In Phase III clinical studies, once-weekly exenatideLAR was associated with reduction in HbA1c of 1.3–1.9% over30 weeks of treatment [40,41]. In the DURATION-1 study,which compared once-weekly exenatide LAR with twice-dailyexenatide, HbA1c reductions were significantly greater withthe long-acting versus regular formulation after 30 weeksof treatment (-1.9 vs -1.5%; treatment difference -0.33 [95%CI: -0.54 to -0.12]; p = 0.0023) [41]. Reductions in FPG weresignificantly greater with exenatide LAR versus exenatide(-2.3 vs -1.4 [-42 vs -25 mg/dl]; p < 0.0001), while changes in2-h PPG were significantly lower in patients treated with exena-tide b.i.d. (-5.3 vs -6.9 mmol/l [-96 vs -126 mg/dl];p = 0.0124) [41]. Consistent with these observations, delay ingastric emptying was markedly less pronounced with exenatideLAR than with exenatide [41].
Liraglutide is a second long-acting GLP-1 RA and the firstanalog of human GLP-1 RA, which is administered q.d. Theliraglutide structure includes modifications for attachment of a
Review Yabe & Seino
doi: 10.1586/17446651.2014.949672 Expert Rev. Endocrinol. Metab.
Exp
ert R
evie
w o
f E
ndoc
rino
logy
& M
etab
olis
m D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y 18
2.24
9.24
7.14
on
09/0
3/14
For
pers
onal
use
onl
y.
16-carbon free fatty acid chain that promotes reversible bindingwith plasma proteins, increasing resistance to DPP-4 cleavage,inhibiting renal clearance and extending its half-life to approxi-mately 12 h [42]. The Phase III clinical studies showed a reduc-tion in HbA1c levels of 1.1–1.8% [18,43–46]. Similar to exenatideLAR, head-to-head comparison of once-daily liraglutide versustwice-daily regular exenatide over 26 weeks revealed
significantly greater reductions in HbA1c (-1.12 vs -0.79%;treatment difference -0.33 [95% CI: -0.47 to -0.18]) and FPG(-1.61 vs -0.60 mmol/l [29 vs 11 mg/dl]; p < 0.0001), but sig-nificantly lower reductions in PPG after breakfast and din-ner [18]. Two recent meta-analyses revealed that exenatide LARand liraglutide showed similar reductions in HbA1c levels, butthat these reductions were superior to those seen with twice-
Table 1. Summary of approved short- and long-acting glucagon-like peptide-1 receptor agonists for thetreatment of type 2 diabetes.
Peptideorigin
Modifications Half-life Dosingregimen
Glucose-loweringeffect and changein body weight
Ref.
Short-acting GLP-1 receptor agonists
Exenatide Exendin-4 Synthetic Exendin-4:
39-amino acids with
53% homology to
human GLP-1. An
Ala2Gly substitution
(relative to human
GLP-1) gives resistance
to DPP-mediated
inactivation
~2.5 h b.i.d. HbA1c
reduction: 0.8–0.9%,
body weight
reduction:
1.6–2.8 kg, over
30 weeks
[25–27]
Lixisenatide Exendin-4 Pro38 removed and
C-terminus modified
with six additional Lys
residues
2–4 h q.d. HbA1c
reduction: 0.7–0.9%,
body weight
reduction:
1.6–3.0 kg, over
24 weeks
[37]
Long-acting GLP-1 receptor agonists
Exenatide
long-acting release
Exendin-4 Exendin-4
administered in a
matrix of
biodegradable polymer
(poly-D,L-lactide-co-
glycolide), resulting in
a release over time
after administration
~2 weeks Once weekly HbA1c
reduction: 1.3–1.9%,
body weight
reduction:
2.3–3.7 kg, over
30 weeks
[40,41,118,119]
Liraglutide GLP-1 Lys34Arg substitution,
and addition of a
C-16 fatty acid
(palmitoyl) at Lys26,
attached by a
glutamate linker
12 h q.d. HbA1c reduction:
1.1–1.8%, body
weight reduction:
0.2–3.2 kg, over
26 week
[18,43–46]
Albiglutide GLP-1 Dimer of a 30 amino
acid peptide, with an
Ala2Glu substitution to
increase resistance to
DPP-4, and fused to
human albumin
6–7 days Once weekly HbA1c
reduction:0.8%,
body weight
reduction: 0.6 kg,
over 32 weeks
[51]
Dulaglutide GLP-1 Covalently linked to an
Fc fragment of human
IgG4
90 h Once weekly HbA1c reduction:
0.8–1.1%, body
weight reduction:
2.6–3.0 kg, over
52 weeks
[120]
b.i.d.: Twice daily; DDP-4: Dipeptidyl peptidase 4; FPG: Fasting plasma glucose; GLP-1: Glucagon-like peptide-1; PPG: Postprandial plasma glucose; q.d.: Once daily.
Defining the role of GLP-1 RAs for individualized treatment of type 2 diabetes Review
informahealthcare.com doi: 10.1586/17446651.2014.949672
Exp
ert R
evie
w o
f E
ndoc
rino
logy
& M
etab
olis
m D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y 18
2.24
9.24
7.14
on
09/0
3/14
For
pers
onal
use
onl
y.
daily exenatide [47,48]. However, a head-to-head trial of liraglu-tide and exenatide LAR found that while both resulted inimprovements in glycemic control, greater reductions inHbA1c, reduced persistence of nausea and fewer occurrences ofhypoglycemia were seen with once-daily liraglutide [49].
The most recent GLP-RA to be approved is albiglutide.Albiglutide is a fusion peptide composed of two DPP-4-resist-ant GLP-1 analogs non-reversibly bound to human serumalbumin, resulting in a half-life of 6–7 days [50]. Data wererecently published from a 32-week Phase III study comparingonce-weekly albiglutide with once-daily liraglutide, whichshowed a reduction in HbA1c of -0.78 versus -0.99%, respec-tively (treatment difference 0.21% [95% CI: 0.08–0.34];p = 0.0846 for non-inferiority) [51]. However, while patientswho received once-daily liraglutide had greater reductions inHbA1c, they also experienced more gastrointestinal side effects,though fewer injection site reactions, than patients whoreceived once-weekly albiglutide [51].
Safety issues associated with the use of GLP-1 RAsOne of the principal attractive features of GLP-1 RAs, in addi-tion to their glucose-lowering benefits, is the relatively low riskof hypoglycemia associated with these agents. GLP-1-inducedstimulation of insulin is glucose-dependent and is negligibleunder conditions of hypoglycemia [52]. Consequently, hypogly-cemia associated with GLP-1 RAs is markedly lower than withsome other anti-diabetic therapies [53,54]. A meta-analysis of27 randomized controlled studies of non-insulin anti-diabeticagents added to metformin therapy showed that GLP-1 RAswere associated with levels of hypoglycemia comparable withplacebo [53]. In contrast, treatment with thiazolidinediones, sul-fonylureas (SUs) and glinides resulted in an increase in hypo-glycemia 2, 2.6- and 7-fold greater than placebo, respectively.As GLP-1 receptor activation by the GLP-1 RA exenatide hasbeen shown to ameliorate ATP production in pancreatic b-cellsand enhance sensitivity to SU [55,56], caution needs to takenwith respect to the potential for hypoglycemia whenGLP-1 RAs are used in combination with SU.
The most common class of adverse events (AEs) experiencedby patients receiving GLP-1 RAs are gastrointestinal AEs. In ameta-analysis of clinical studies of GLP-1 RAs versus insulin, asignificantly greater proportion of patients treated withGLP-1 RAs experienced gastrointestinal AEs compared withthose treated with insulin (Mantel–Haenszel odds ratio 15.00[5.44, 41.35]; p < 0.01) [57]. A review and meta-analysis ofGLP-1 RAs and DPP-4 inhibitors as an add-on to metforminby Deacon et al. found that while AEs were rare overall, theincidence of nausea and vomiting increased with GLP-1 RAtreatment [48]. However, it should also be noted that these gas-trointestinal side effects were mild to moderate in intensity,rarely resulting in treatment withdrawal, were transient in themajority of cases [37,58–60] and the frequency of events appearedto decline over the first few weeks of treatment [61]. The risk ofgastrointestinal side effects may also be influenced by dosingtitration, meal size, meal frequency and BMI.
While short-acting GLP-1 RAs, such as exenatide and lixise-natide, have been associated with a small or non-significanteffect, or even a reduction in resting heart rate, several long-acting GLP-1 RAs, including dulaglutide, liraglutide and LARexenatide, have been shown to be associated with a significantincrease in resting heart rate [62,63]. A significant effect ofGLP-1 RAs on electrocardiogram QT intervals has not beendemonstrated [64–66]. Administration of liraglutide 0.6, 1.2 or1.8 mg q.d. over 7 days found no concentration–exposuredependency on QTc intervals compared with placebo, and noQTc thresholds 500 ms or increases over >60 ms [64], andsingle-dose exenatide 10 mg was not found to be associatedwith clinically meaningful prolongation of the QTc interval,compared with placebo, in healthy subjects [66]. Analysis ofcardiovascular events from Phase II and Phase III liraglutidestudies demonstrated that the overall risk of cardiovascularevents was low, meeting the US FDA criteria for ruling outunacceptable increases in cardiovascular risk [67]. Data fromongoing long-term large-scale cardiovascular outcomes studiesare needed to confirm the lack of cardiovascular risk withGLP-1 RAs [68,69].
Acute pancreatitis is another rare but potentially serioussafety issue with regard to use of GLP-RAs and DPP-4 inhibi-tors. Concerns were raised initially on the basis of individualcase reports in exenatide- and liraglutide-treated patients [70],and retrospective analyses of medical databases [71]. However,both of these sources of information can be unrepresentative ofthe clinical reality and subject to potential bias. Evidence fromrandomized clinical studies of GLP-1 RAs provides a more rig-orous assessment and has not identified a link, although thestatistical power of individual studies is limited for detectingsuch a rare event [72]. More recently, a meta-analysis of 41 ran-domized clinical studies with GLP-1 RAs showed no increasein the risk of pancreatitis with the use of GLP-1 RAs [73], andrecent incretin pancreatic safety reviews by both the FDA andEMA found no evidence of a causal relationship [74]. Concernshave also been raised regarding a potential increased risk ofmedullary thyroid cancer with GLP-1 RAs based on evidenceof thyroid C-cell hyperplasia and tumors associated with long-term liraglutide exposure in rodents [75]. However, large-scalemonitoring during clinical studies has not identified any indica-tors of cancer development, and no increased incidence of C-cell cancer was identified during the clinical studies of otherGLP-1 RAs [76]. An analysis of data reported to the FDAadverse event reporting system did seem to show an increasedrisk of pancreatic and thyroid cancer with incretin therapies,although the data were not consistent and have been discred-ited on the basis of a bias in reporting of events [77,78].
Predictors of efficacy for GLP-1 RAsBaseline HbA1c
A meta-analysis that included seven studies relating to short-acting GLP-1 RAs and seven studies relating to long-actingGLP-1 RAs identified a linear significant negative correlationbetween baseline HbA1c and reduction in HbA1c in both
Review Yabe & Seino
doi: 10.1586/17446651.2014.949672 Expert Rev. Endocrinol. Metab.
Exp
ert R
evie
w o
f E
ndoc
rino
logy
& M
etab
olis
m D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y 18
2.24
9.24
7.14
on
09/0
3/14
For
pers
onal
use
onl
y.
groups over the course of the studies, with a significantlygreater reduction seen in the long-acting GLP-1 RA group [48].Similarly, Kawata et al. identified HbA1c at baseline as the sin-gle largest predictive factor for reduction in HbA1c with liraglu-tide, with significant associations seen at 12 weeks after thestart of liraglutide (b = -0.854, p = 0.001) and at 24 weeks(b = -0.602, p = 0.013) [79]. The authors concluded that base-line HbA1c may be a predictive factor for HbA1c reduction forall incretin therapies, and this could explain why increasedbaseline HbA1c is associated with a greater degree of HbA1c
reduction on treatment with liraglutide.
Ethnicity
Accumulating evidence suggests that GLP-1RAs exert a greatereffect on glycemic control in Asian patients than in non-Asianpatients [80]. In a study comparing the efficacy of lixisenatide inJapanese and Caucasian patients with T2DM insufficiently con-trolled with SU with or without metformin, Japanese patientsexperienced a greater benefit in terms of reduction in PPG excur-sions compared with Caucasian patients [81]. In Japanese patients,the LS mean difference versus placebo in PPG AUC[0:29–4:30 h]
after a standardized breakfast was -406.7 (36.7) h•mg/dl for thelixisenatide q.d. group and -346.3 (35.1) h•mg/dl for the lixise-natide b.i.d. group compared with -260.1 (39.5) h•mg/dl and-231.3 (38.6) h•mg/dl, respectively, in Caucasian patients [81].The authors suggest that greater efficacy of GLP-1 RAs in Asianpatients may be attributable to lower insulin secretory capacity [82]
along with little enhancement of meal-induced GLP-1 secretionin Japanese subjects [83,84].
Residual b-cell function
Pancreatic b-cells are critical for regulation of glucose homeosta-sis, and their progressive loss is a cardinal symptom of T2DMthat underlies the progression of deteriorating glucose control.Long-acting GLP-RAs significantly improve glycemic controlpartly by stimulating insulin release from pancreatic b-cells,unlike short-acting GLP-RAs, which act primarily througheffects on gastric motility. This difference in mechanism ofaction suggests that a certain amount of residual b-cell functionis required for optimal efficacy of long-acting GLP-1 RAs, whileresidual b-cell function is less important for the efficacy ofshort-acting GLP-1 RAs, such as exenatide and lixisenatide. Evi-dence in support of this hypothesis comes from an analysis ofdata from the Phase III studies of liraglutide, which showed asignificantly greater beneficial effect on HbA1c, with liraglutideversus exenatide in patients with high-estimated b-cell mass butno difference in patients with low-estimated b-cell mass [85]. Incontrast, a similar pooled analysis of data from two Phase IIIstudies of short-acting lixisenatide showed that HbA1c reduc-tions were consistent regardless of patients’ b-cell function, andthat PPG reductions were actually significantly greater inpatients with low- versus high-residual b-cell function [17].
The clinical importance of b-cell function for the efficacy oflong-acting GLP-1 RAs has been shown in a recent analysis ofpatients with T2DM switching from insulin to liraglutide
therapy [86]. Patients whose hyperglycemia was uncontrolledafter 12 weeks of liraglutide therapy had a longer duration ofdiabetes, higher baseline insulin doses and lower b-cell functioncompared with responders, indicating a more advanced stageof disease.
Gender
Treatment of T2DM with twice-daily exenatide 10 mg as anadd-on to oral therapy (metformin or metformin ± SU) hasbeen shown to result in better glycemic control in male patientsthan in female patients after 12 months of treatment, withHbA1c £7% achieved in a significantly greater proportion ofmales than females (38 vs 27%). With regard to safety, nosignificant gender difference regarding gastrointestinal AEs hasbeen reported; for example, 60 and 63 cases of nausea werereported with exenatide therapy in males and females,respectively [87].
Predictors of achieving therapeutic glycemic response (HbA1c
£7%) at 1 year among males were found to be inversely relatedto a longer duration of disease and baseline HcA1c. In females,baseline therapy with metformin was related to a positive glyce-mic outcome at 1 year, and baseline SU treatment or combina-tion treatment was associated with a negative effect onachievement of glycemic targets. In females only, an increase inbaseline homeostatic model assessment-b was also associatedwith a positive glycemic response [87].
Expectations beyond glycemic controlThe benefit of improved glycemic control with a low risk ofhypoglycemia makes the GLP-1 RAs an attractive treatmentoption in T2DM. However, the multiple physiologicaleffects of GLP-1 indicate that the clinical benefits ofGLP-1 RAs are likely to extend further (FIGURE 1). Preclinicalstudies of animal models indicate that incretins play a role ina range of diverse biological activities, with potential implica-tions for improvements in diabetes-related microvascularcomplications (e.g., retinopathy, nephropathy and neuropa-thy) and macrovascular complications (e.g., coronary arterydisease, peripheral artery disease and cerebrovascular disease),as well as diabetes-related comorbidities (e.g., obesity,non-alcoholic fatty liver disease, bone fracture and cognitivedysfunction) [88–90].
GLP-1 RAs have a clinically demonstrable benefit in termsof weight, which can be helpful in ameliorating early T2DMand the effects of weight gain from other anti-diabetictherapies [91–93]. A meta-analysis of 25 randomized controlledstudies of GLP-1 RAs of at least 20 weeks’ duration showedthat weight decrease was a consistent phenomenon, with areduction in body weight of approximately 2.9 kg per study [94].Another meta-analysis that included 29 randomized controlledstudies of GLP-1 RAs of at least 24 weeks’ duration reported areduction in BMI at 6 months of -1.0 kg/m2
[95]. Comparablereductions in weight were seen with short- and long-actingGLP-1 RAs. Weight decrease with GLP-1 RAs is thought tooccur through delayed gastric emptying and neurological
Defining the role of GLP-1 RAs for individualized treatment of type 2 diabetes Review
informahealthcare.com doi: 10.1586/17446651.2014.949672
Exp
ert R
evie
w o
f E
ndoc
rino
logy
& M
etab
olis
m D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y 18
2.24
9.24
7.14
on
09/0
3/14
For
pers
onal
use
onl
y.
suppression of appetite by increasing the perception of fullnessand satiety [96]. As the effects of long-acting GLP-1 RAs ongastric emptying could be lost with sustained dosing, as dis-cussed above, the fact that weight reduction with GLP-1 RAsis independent of the duration of action highlights the impor-tance of GLP-1 RA-mediated suppression of appetite via thebrain [20]. The potential for weight decrease with GLP-1 RAs isan attractive feature, particularly for patients with considerableobesity and for those needing intensified therapy with a treat-ment option that may contribute to an increase body weight,such as insulin.
Studies in animals show that GLP-1 RAs may have potentialcardioprotective effects [88,90,97]. In patients with acute myocar-dial infarction and left ventricular ejection fraction dysfunction,GLP-1 infused over 72 h significantly improved left ventricularejection fraction, and other measures of cardiac function,including global wall motion indices and regional wallmotion [98]. More recently, it was reported that GLP-1 infusionprotects the heart from ischemic left ventricle dysfunctioninduced by dobutamine stress in patients with coronary arterydisease [99]. Exenatide has also been shown to reduce reperfu-sion injury and final infarct size in patients with ST-segmentelevated myocardial infarction [100,101].
GLP-1 RAs also have well-documented benefits against riskfactors for cardiovascular disease, including hypertension anddyslipidemia. The anti-hypertensive effects of GLP-1 have consis-tently been shown in several clinical studies. A meta-analysis of
16 randomized controlled studies of GLP-1 RAs in patients withT2DM revealed that GLP-1 RAs reduced systolic blood pressureand diastolic blood pressure by 1–5 mmHg compared with someother anti-diabetic drugs including insulin, glimepiride and pla-cebo [102]. A pooled analysis of six Phase III clinical trials with lir-aglutide also found significantly greater systolic blood pressurereductions from baseline with liraglutide 1.2 mg q.d. (2.7 [0.8]mmHg) and 1.8 mg (2.9 [0.7] mmHg) than with placebo (0.5[0.9] mmHg) (p = 0.0029 and p = 0.0004, respectively), after26 weeks [103]. Measurement of flow-mediated vasodilatation ofthe brachial artery in patients with T2DM has shown a signifi-cantly greater increase in flow-mediated vasodilatation with exe-natide versus glimepiride [104]. In mice, activation of GLP-1receptors expressed in cardiac atria has been shown to stimulateatrial natriuretic peptide production, a powerful vasodilator [105],indicating that GLP-1 RAs exert their anti-hypertensive effectsthrough a vasodilatory action.
GLP-1 infusion inhibits postprandial elevation of triglyceridesand free fatty acids in healthy individuals [106]. A single subcuta-neous injection of exenatide in patients with newly diagnosedT2DM was also associated with a marked reduction in postpran-dial triacylglycerol, as well as in apolipoprotein B48 [107].Whether these effects on triglycerides and free fatty acids are aresult of delayed gastric emptying or some other mechanism hasyet to be determined. Nevertheless, the data show thatGLP-1 receptor activation ameliorates postprandial lipidemia,which is likely to be beneficial for patients with T2DM.
Extrapancreatic actions Macrovascular Microvascular Co-morbidities
Cerebrovasculardisease
GLP-1: Prevent
Cardiovasculardisease
GLP-1: Prevent
RetinopathyGLP-1: Prevent
DementiaGLP-1: Improve
Fatty liverGLP-1: Improve
ObesityGLP-1: Improve
Bone fractureGLP-1: Prevent
NephropathyGLP-1: Prevent
NeuropathyGLP-1: Prevent
HypertensionGLP-1: Improve
DyslipidemiaGLP-1: Improve
InflammationGLP-1: Prevent
Peripheral arterydisease
GLP-1: Prevent
Intrapancreatic actions
Insulin secretionGLP-1: Stimulate
Glucagon secretionGLP-1: Suppress
β cell massGLP-1: Increase
Figure 1. Intra- and extrapancreatic function of glucagon-like peptide-1 and expected effects on diabetic complications andco-morbidities.GLP-1: Glucagon-like peptide-1.Adapted with permission from [90] � Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd (2013).
Review Yabe & Seino
doi: 10.1586/17446651.2014.949672 Expert Rev. Endocrinol. Metab.
Exp
ert R
evie
w o
f E
ndoc
rino
logy
& M
etab
olis
m D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y 18
2.24
9.24
7.14
on
09/0
3/14
For
pers
onal
use
onl
y.
GLP-1 RAs as add-on therapies in clinical useMeta-analyses comparing multiple different add-on therapies tometformin for treatment of T2DM have reported that treat-ment with add-on GLP-1 RAs was as effective as basal orbiphasic insulin in terms of glycemic control [54] and resultedin a greater decrease in HbA1c compared with adjunctive SU,glinides, thiazolidinediones, a-glucosidase inhibitors andDPP-4 inhibitors [48,54]. In a meta-analysis comparing metfor-min in combination with either DPP-4 inhibitors orGLP-1 RAs, both were found to significantly reduce HbA1c,but long-term concomitant treatment with metformin andlong-acting GLP-1 RAs (liraglutide or exenatide once weekly)were associated with significantly greater reductions in FPGthan add-on treatment with short-acting exenatide (b.i.d.) orDPP-4 inhibitors [48]. The addition of short-acting agents tobasal insulin has been shown to be effective in achievingHbA1c targets in patients with T2DM insufficiently controlledwith basal insulin alone [91,108–111]. In particular, the additionof short-acting GLP-1 RAs to basal insulin is a favorableoption for treatment intensification in patients with T2DMdue to complementary effects on PPG and FPG, respectively,and can result in improved overall glycemic control versus basalinsulin alone [112–114]. The efficacy of long-acting GLP-1 RAsto basal insulin still needs to be compared with that of short-acting GLP-1 RAs in clinical trials in the future.
Some T2DM therapy combinations are associated withweight increase. While add-on treatment with DPP-4 inhibitorsis reported to be weight-neutral, [48,53,54,115], SU, glinides, thiazo-lidinediones, basal insulin and biphasic insulin add-on therapiesare associated with weight increase. By contrast, botha-glucosidase inhibitors [53,54] and GLP-1 RAs as add-on thera-pies have been associated with weight decrease [48,53,54,115].The addition of GLP-1 RAs to basal insulin is associated withsignificant weight reduction compared with placebo plus basalinsulin [114,116], which may be of particular clinical importanceand relevance to patients.
A final important consideration for add-on therapy regimensis the risk of hypoglycemia. Neither DPP-4 inhibitors norGLP-1 RAs in combination with metformin were associatedwith an increase in the risk of hypoglycemia [54,117]. Additionof GLP-1 RAs to basal insulin was not associated withincreased risk of hypoglycemia compared with basal insulinalone [114,116].
ConclusionIncretin-based therapy, specifically GLP-1 RAs, represent avaluable addition to treatment options for T2DM. A variety ofGLP-1 RAs are available which, due to differing mechanismsof action, provide different clinical profiles. Long-actingGLP-1 RAs help patients reach glycemic targets through FPGand PPG control as a result of insulinotropic effects, whereasshort-acting GLP-1 RAs confer overall glycemic controlthrough pronounced effects on PPG, mainly as a result ofdelayed gastric emptying. Safety and tolerability profiles alsodiffer somewhat between agents, although gastrointestinal
events remain the most common type of AE with this class ofdrug. Beyond the glycemic control actions of GLP-1 RAs, thesedrugs are also associated with multiple physiological effects,with potential implications for improvements in diabetes-related microvascular and macrovascular complications, as wellas diabetes-related comorbidities. GLP-1 RAs are associatedwith reduced weight increase or even weight decrease. Finally,GLP-1 RAs represent an attractive option as add-on therapyfor patients who may not have adequate glycemic control withtheir existing treatment regimen. In particular, the addition ofshort-acting GLP-1 RAs to basal insulin represents a clinicallyuseful treatment option for patients with inadequate PPG con-trol despite well-controlled FPG.
In summary, GLP-1 RAs represent an effective and well-tolerated treatment option for many different types of patientswith T2DM.
Expert commentaryIt has been thought that GLP-1 RAs improve glycemia by bothameliorating impaired secretion of insulin and glucagon, andby delaying gastric emptying. Accumulating evidence showsthat the primary mode of action is different among differentGLP-1 RAs; long-acting GLP-1 RAs acting preferentially viapancreatic b-cells, while short-acting GLP-1 RAs do so mainlyvia delayed gastric emptying. Such differences are reflected bydifferential effects of long- and short-acting GLP-1 RAs onfasting and postprandial glucose levels, although effects arecomparable on body weight changes. Although it remains to betested in clinical trials, our current knowledge strongly suggeststhat long-acting GLP-1 RAs ameliorate glycemia more effi-ciently in patients with sufficient b-cell function, while short-acting GLP-1 RAs, possibly combined with basal insulin, couldimprove postprandial glucose excursions even in patients withlow b-cell function.
Five-year viewWhile long-term efficacy of GLP-1 RAs in glucose loweringand body weight reduction have been documented over theyears, beneficial effects on diabetes complications (e.g., micro-and macroangiopathies) need to be assessed through large-scalerandomized clinical trials, along with any potential AE risks (e.g., pancreatic diseases). Meanwhile, development of once-weekly or once-monthly GLP-1 RAs, as well as oral or nasalGLP-1 RAs, should be continued to improve the quality of lifeof patients with T2DM.
Financial & competing interests disclosure
D Yabe has taken part in advisory panels for Sanofi, Novo Nordisk, Inc.
and Novartis Pharma AG, and has taken part in speaker’ s bureaux for
Sanofi, Novo Nordisk Inc., Merck Sharp & Dohme Limited, Takeda
Pharmaceuticals USA, Inc., Boehringer Ingelheim Pharmaceuticals, Inc.,
Eli Lilly and Company and Bristol-Myers Squibb Company. Y Seino
has acted as medical advisor for Eli Lilly, Sanoi, Novo Nordisk,
GlaxoSmithKline, Taisho Pharmaceuticals, Astellas Pharmaceuticals,
Becton, Dickinson & Company, Boerhringer Ingelheim, Johnson &
Defining the role of GLP-1 RAs for individualized treatment of type 2 diabetes Review
informahealthcare.com doi: 10.1586/17446651.2014.949672
Exp
ert R
evie
w o
f E
ndoc
rino
logy
& M
etab
olis
m D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y 18
2.24
9.24
7.14
on
09/0
3/14
For
pers
onal
use
onl
y.
Johnson, Takeda Pharmaceuticals and Otsuka Pharmaceuticals. The
authors have no other relevant affiliations or financial involvement with
any organization or entity with a financial interest in or financial conflict
with the subject matter or materials discussed in the manuscript apart
from those disclosed. Writing and editorial assistance was provided by
A Shepherd of Caudex Medical, funded by Sanofi.
Key issues
• Patients with type 2 diabetes mellitus (T2DM) demonstrate an impaired capability to regulate their incretin effect, and correction of this
dysfunction with exogenous glucagon-like peptide-1, GLP-1 receptor agonists (GLP-1 RAs), has become established as an important
treatment strategy for T2DM, with an efficacy and safety profile distinct from that of other anti-diabetic agents.
• The different GLP-1 RAs approved for use in patients with poorly controlled T2DM can be divided into two broad categories according
to their relative half-lives as short- and long-acting GLP-1 RAs, which exert their glucose-lowering effects through different dominant
mechanistic actions: delayed gastric emptying and enhanced insulin secretion.
• Short-acting GLP-1 RAs have limited effects on insulin and glucagon secretion, but have a delaying effect on gastric emptying, which
results in pronounced reductions in postprandial plasma glucose (PPG) levels by reducing the rate of glucose absorption from the
small intestine.
• Long-acting GLP-1 RAs have a limited effect on gastric emptying, but provide reductions in fasting plasma glucose (FPG) and PPG – the
latter less robustly than short-acting GLP-1RAs – through amelioration of insulin and glucagon secretion.
• The clinical implication of these mechanistic differences is that short-acting GLP-RAs are better suited to improve control of PPG
excursions, even in patients with limited residual b-cell function, while long-acting GLP-1 RAs are more appropriate for patients needing
control of FPG, in addition to PPG, but require a certain amount of residual b-cell function.• Compared with thiazolidinediones, sulfonylureas and glinides, GLP-1 RAs are associated with a relatively low risk of hypoglycemia, as
GLP-1-induced stimulation of insulin is glucose-dependent and is negligible under conditions of hypoglycemia, although caution is
advised if GLP-1 RAs are used in combination with sulfonylureas, as they may enhance b-cell sensitivity to this agent.
• Both short- and long-acting GLP-1 RAs have a clinically demonstrable benefit in terms of weight, which can be helpful in ameliorating
early T2DM and the effects of weight gain from other anti-diabetic therapies, such as insulin.
• GLP-1 RAs also have well-documented benefits against risk factors for cardiovascular disease, including hypertension and dyslipidemia.
• The most common class of adverse events experienced by patients receiving GLP-1 RAs are gastrointestinal adverse events, and
although concerns have been raised about a potential increased risk of acute pancreatitis, thyroid C-cell hyperplasia and tumors, no
increased risk has been identified.
• GLP-1 RAs represent an attractive option as add-on therapy for patients who may not have adequate glycemic control with their
existing treatment regimen, and in particular, the addition of GLP-1 RAs to basal insulin represents a clinically useful treatment option
for patients with inadequate PPG control and body weight gain despite well-controlled FPG.
References
Papers of special note have been highlighted as:
• of interest
1. Defronzo RA. Banting Lecture. From the
triumvirate to the ominous octet: a new
paradigm for the treatment of type 2
diabetes mellitus. Diabetes 2009;58(4):
773-95
2. Seino Y, Fukushima M, Yabe D. GIP and
GLP-1, the two incretin hormones:
similarities and differences. J Diabetes
Investig 2010;1(1-2):8-23
3. Campbell JE, Drucker DJ. Pharmacology,
physiology, and mechanisms of incretin
hormone action. Cell Metab 2013;17(6):
819-37
4. Deane AM, Nguyen NQ, Stevens JE, et al.
Endogenous glucagon-like peptide-1 slows
gastric emptying in healthy subjects,
attenuating postprandial glycemia. J Clin
Endocrinol Metab 2010;95(1):215-21
5. Edwards CM, Stanley SA, Davis R, et al.
Exendin-4 reduces fasting and postprandial
glucose and decreases energy intake in
healthy volunteers. Am J Physiol Endocrinol
Metab 2001;281(1):E155-61
6. Flint A, Raben A, Ersboll AK, et al. The
effect of physiological levels of glucagon-like
peptide-1 on appetite, gastric emptying,
energy and substrate metabolism in obesity.
Int J Obes Relat Metab Disord 2001;25(6):
781-92
7. Meier JJ, Gallwitz B, Salmen S, et al.
Normalization of glucose concentrations and
deceleration of gastric emptying after solid
meals during intravenous glucagon-like
peptide 1 in patients with type 2 diabetes.
J Clin Endocrinol Metab 2003;88(6):
2719-25
8. Holst JJ. The physiology of glucagon-like
peptide 1. Physiol Rev 2007;87(4):1409-39
9. Bagger JI, Knop FK, Lund A, et al.
Impaired regulation of the incretin effect in
patients with type 2 diabetes. J Clin
Endocrinol Metab 2011;96(3):737-45
10. Deacon CF, Nauck MA, Toft-Nielsen M,
et al. Both subcutaneously and intravenously
administered glucagon-like peptide I are
rapidly degraded from the NH2-terminus in
type II diabetic patients and in healthy
subjects. Diabetes 1995;44(9):1126-31
11. Meier JJ, Nauck MA, Kranz D, et al.
Secretion, degradation, and elimination of
glucagon-like peptide 1 and gastric
inhibitory polypeptide in patients with
chronic renal insufficiency and healthy
control subjects. Diabetes 2004;53(3):
654-62
Review Yabe & Seino
doi: 10.1586/17446651.2014.949672 Expert Rev. Endocrinol. Metab.
Exp
ert R
evie
w o
f E
ndoc
rino
logy
& M
etab
olis
m D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y 18
2.24
9.24
7.14
on
09/0
3/14
For
pers
onal
use
onl
y.
12. Ahren B, Schmitz O. GLP-1 receptor
agonists and DPP-4 inhibitors in the
treatment of type 2 diabetes. Horm Metab
Res 2004;36(11-12):867-76
13. Garber AJ. Incretin-based therapies in the
management of type 2 diabetes: rationale
and reality in a managed care setting. Am J
Manag Care 2010;16(Suppl 7):S187-94
14. Ahren B, Gautier JF, Berria R, et al.
Pronounced reduction of post-prandial
glucagon by lixisenatide: a meta-analysis of
randomized clinical trials. Diabetes Obes
Metab 2014. [Epub ahead of print]
15. Shah P, Vella A, Basu A, et al. Lack of
suppression of glucagon contributes to
postprandial hyperglycemia in subjects with
type 2 diabetes mellitus. J Clin Endocrinol
Metab 2000;85(11):4053-9
16. Lorenz M, Pfeiffer C, Steinstrasser A, et al.
Effects of lixisenatide once daily on gastric
emptying in type 2 diabetes - Relationship
to postprandial glycemia. Regul Pept 2013;
185(1):8
17. Meier JJ, Yabe D, Wang E, et al. Efficacy
of lixisenatide in patients with different
levels of beta cell function as assessed by C-
peptide/glucose ratio. Diabetologia 2013;
56(Suppl 1):S1-S566; Abstract 896
• A study that demonstrates the significant
role of gastric emptying and glucagon
inhibition in the mechanism of glycemic
control with the short-acting glucagon-
like peptide-1 receptor agonist (GLP-1
RA), lixisenatide.
18. Buse JB, Rosenstock J, Sesti G, et al.
Liraglutide once a day versus exenatide
twice a day for type 2 diabetes: a 26-week
randomised, parallel-group, multinational,
open-label trial (LEAD-6). Lancet 2009;
374(9683):39-47
19. Degn KB, Juhl CB, Sturis J, et al. One
week’s treatment with the long-acting
glucagon-like peptide 1 derivative liraglutide
(NN2211) markedly improves 24-h
glycemia and alpha- and beta-cell function
and reduces endogenous glucose release in
patients with type 2 diabetes. Diabetes
2004;53(5):1187-94
20. Meier JJ. GLP-1 receptor agonists for
individualized treatment of type 2 diabetes
mellitus. Nat Rev Endocrinol 2012;8(12):
728-42
21. Kolterman OG, Buse JB, Fineman MS,
et al. Synthetic exendin-4 (exenatide)
significantly reduces postprandial and fasting
plasma glucose in subjects with type 2
diabetes. J Clin Endocrinol Metab 2003;
88(7):3082-9
22. Goke R, Fehmann HC, Linn T, et al.
Exendin-4 is a high potency agonist and
truncated exendin-(9-39)-amide an
antagonist at the glucagon-like peptide 1-(7-
36)-amide receptor of insulin-secreting beta-
cells. J Biol Chem 1993;268(26):19650-5
23. FDA. Amylin Pharmaceuticals Inc. Byetta
prescribing information. 2009
24. Bristol-Myers Squibb and AstraZeneca
EEIG. Byetta: Summary of product
characteristics. EMA. 2012
25. Defronzo RA, Ratner RE, Han J, et al.
Effects of exenatide (exendin-4) on glycemic
control and weight over 30 weeks in
metformin-treated patients with type 2
diabetes. Diabetes Care 2005;28(5):
1092-100
26. Kendall DM, Riddle MC, Rosenstock J,
et al. Effects of exenatide (exendin-4) on
glycemic control over 30 weeks in patients
with type 2 diabetes treated with metformin
and a sulfonylurea. Diabetes Care 2005;
28(5):1083-91
27. Buse JB, Henry RR, Han J, et al. Effects of
exenatide (exendin-4) on glycemic control
over 30 weeks in sulfonylurea-treated
patients with type 2 diabetes. Diabetes Care
2004;27(11):2628-35
28. Heine RJ, Van Gaal LF, Johns D, et al.
Exenatide versus insulin glargine in patients
with suboptimally controlled type 2
diabetes: a randomized trial. Ann Intern
Med 2005;143(8):559-69
29. Thorkildsen C, Neve S, Larsen BD, et al.
Glucagon-like peptide 1 receptor agonist
ZP10A increases insulin mRNA expression
and prevents diabetic progression in db/db
mice. J Pharmacol Exp Ther 2003;307(2):
490-6
30. Werner U, Haschke G, Herling AW,
Kramer W. Pharmacological profile of
lixisenatide: a new GLP-1 receptor agonist
for the treatment of type 2 diabetes. Regul
Pept 2010;164(2-3):58-64
31. Distiller RA, Ruus P; on behalf of the
ACT6011 Study Group. Pharmacokinetics
and pharmacodynamics of a new GLP-1
agonist AVE0010 in type 2 diabetes
patients. Diabetes 2008;58(Suppl 1):A154-5
32. Ratner RE, Rosenstock J, Boka G. Dose-
dependent effects of the once-daily GLP-1
receptor agonist lixisenatide in patients with
Type 2 diabetes inadequately controlled
with metformin: a randomized, double-
blind, placebo-controlled trial. Diabet Med
2010;27(9):1024-32
33. Ahren B, Leguizamo DA, Miossec P, et al.
Efficacy and safety of lixisenatide once-daily
morning or evening injections in type 2
diabetes inadequately controlled on
metformin (GetGoal-M). Diabetes Care
2013;36(9):2543-50
34. Bolli GB, Munteanu M, Dotsenko S, et al.
Efficacy and safety of lixisenatide once daily
versus placebo in patients with type 2
diabetes insufficiently controlled on
metformin (GetGoal-F1). Diabet Med
2014;31:176-84
35. Pinget M, Goldenberg R, Niemoeller E,
et al. Efficacy and safety of lixisenatide once
daily versus placebo in type 2 diabetes
insufficiently controlled on pioglitazone
(GetGoal-P). Diabetes Obes Metab 2013;
15(11):1000-7
36. Rosenstock J, Raccah D, Koranyi L, et al.
Efficacy and safety of lixisenatide once daily
versus exenatide twice daily in type 2
diabetes inadequately controlled on
metformin: a 24-week, randomized, open-
label, active-controlled study (GetGoal-X).
Diabetes Care 2013;36(10):2945-51
37. Bolli GB, Owens DR. Lixisenatide, a novel
GLP-1 receptor agonist: efficacy, safety and
clinical implications for type 2 diabetes
mellitus. Diabetes Obes Metab 2014;16(7):
588-601
38. Ahren B. Equal improvement in glycemia
with lixisenatide given before breakfast or
the main meal of the day. J Diabetes
Complications 2014. [Epub ahead of print]
39. Fineman M, Flanagan S, Taylor K, et al.
Pharmacokinetics and pharmacodynamics of
exenatide extended-release after single and
multiple dosing. Clin Pharmacokinet 2011;
50(1):65-74
40. Bergenstal RM, Wysham C, Macconell L,
et al. Efficacy and safety of exenatide once
weekly versus sitagliptin or pioglitazone as
an adjunct to metformin for treatment of
type 2 diabetes (DURATION-2): a
randomised trial. Lancet 2010;376(9739):
431-9
41. Drucker DJ, Buse JB, Taylor K, et al.
Exenatide once weekly versus twice daily for
the treatment of type 2 diabetes: a
randomised, open-label, non-inferiority
study. Lancet 2008;372(9645):1240-50
42. Agerso H, Jensen LB, Elbrond B, et al. The
pharmacokinetics, pharmacodynamics, safety
and tolerability of NN2211, a new long-
acting GLP-1 derivative, in healthy men.
Diabetologia 2002;45(2):195-202
43. Garber A, Henry R, Ratner R, et al.
Liraglutide versus glimepiride monotherapy
for type 2 diabetes (LEAD-3 Mono): a
randomised, 52-week, phase III, double-
blind, parallel-treatment trial. Lancet 2009;
373(9662):473-81
Defining the role of GLP-1 RAs for individualized treatment of type 2 diabetes Review
informahealthcare.com doi: 10.1586/17446651.2014.949672
Exp
ert R
evie
w o
f E
ndoc
rino
logy
& M
etab
olis
m D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y 18
2.24
9.24
7.14
on
09/0
3/14
For
pers
onal
use
onl
y.
44. Marre M, Shaw J, Brandle M, et al.
Liraglutide, a once-daily human GLP-1
analogue, added to a sulphonylurea over 26
weeks produces greater improvements in
glycaemic and weight control compared
with adding rosiglitazone or placebo in
subjects with Type 2 diabetes (LEAD-1
SU). Diabet Med 2009;26(3):268-78
45. Nauck M, Frid A, Hermansen K, et al.
Efficacy and safety comparison of
liraglutide, glimepiride, and placebo, all in
combination with metformin, in type 2
diabetes: the LEAD (liraglutide effect and
action in diabetes)-2 study. Diabetes Care
2009;32(1):84-90
46. Zinman B, Gerich J, Buse JB, et al. Efficacy
and safety of the human glucagon-like
peptide-1 analog liraglutide in combination
with metformin and thiazolidinedione in
patients with type 2 diabetes (LEAD-4 Met
+TZD). Diabetes Care 2009;32(7):1224-30
47. Scott DA, Boye KS, Timlin L, et al. A
network meta-analysis to compare glycaemic
control in patients with type 2 diabetes
treated with exenatide once weekly or
liraglutide once daily in comparison with
insulin glargine, exenatide twice daily or
placebo. Diabetes Obes Metab 2013;15(3):
213-23
48. Deacon CF, Mannucci E, Ahren B.
Glycaemic efficacy of glucagon-like peptide-
1 receptor agonists and dipeptidyl peptidase-
4 inhibitors as add-on therapy to metformin
in subjects with type 2 diabetes-a review
and meta analysis. Diabetes Obes Metab
2012;14(8):762-7
49. Buse JB, Nauck M, Forst T, et al.
Exenatide once weekly versus liraglutide
once daily in patients with type 2 diabetes
(DURATION-6): a randomised, open-label
study. Lancet 2013;381(9861):117-24
50. Matthews JE, Stewart MW, De Boever EH,
et al. Pharmacodynamics, pharmacokinetics,
safety, and tolerability of albiglutide, a long-
acting glucagon-like peptide-1 mimetic, in
patients with type 2 diabetes. J Clin
Endocrinol Metab 2008;93(12):4810-17
51. Pratley RE, Nauck MA, Barnett AH, et al.
Once-weekly albiglutide versus once-daily
liraglutide in patients with type 2 diabetes
inadequately controlled on oral drugs
(HARMONY 7): a randomised, open-label,
multicentre, non-inferiority phase 3 study.
Lancet Diabetes Endocrinol 2014;2(4):
289-97
52. Nauck MA, Heimesaat MM, Behle K, et al.
Effects of glucagon-like peptide 1 on
counterregulatory hormone responses,
cognitive functions, and insulin secretion
during hyperinsulinemic, stepped
hypoglycemic clamp experiments in healthy
volunteers. J Clin Endocrinol Metab 2002;
87(3):1239-46
53. Phung OJ, Scholle JM, Talwar M,
Coleman CI. Effect of noninsulin
antidiabetic drugs added to metformin
therapy on glycemic control, weight gain,
and hypoglycemia in type 2 diabetes. JAMA
2010;303(14):1410-18
54. Liu SC, Tu YK, Chien MN, Chien KL.
Effect of antidiabetic agents added to
metformin on glycaemic control,
hypoglycaemia and weight change in
patients with type 2 diabetes: a network
meta-analysis. Diabetes Obes Metab 2012;
14(9):810-20
55. Mukai E, Fujimoto S, Sato H, et al.
Exendin-4 suppresses SRC activation and
reactive oxygen species production in
diabetic Goto-Kakizaki rat islets in an Epac-
dependent manner. Diabetes 2011;60(1):
218-26
56. Yabe D, Seino S. Dipeptidyl peptidase-4
inhibitors and sulfonylureas for type 2
diabetes: Friend or Foe J Diabetes Investig
2014. [Epub ahead of print]
57. Wang Y, Li L, Yang M, et al. Glucagon-like
peptide-1 receptor agonists versus insulin in
inadequately controlled patients with type 2
diabetes mellitus: a meta-analysis of clinical
trials. Diabetes Obes Metab 2011;13(11):
972-81
58. Mulligan CM, Harper R, Harding J, et al.
A retrospective audit of type 2 diabetes
patients prescribed liraglutide in real-life
clinical practice. Diabetes Ther 2013;4(1):
147-51
59. Wysham C, Blevins T, Arakaki R, et al.
Efficacy and safety of dulaglutide added
onto pioglitazone and metformin versus
exenatide in type 2 diabetes in a
randomized controlled trial (AWARD-1).
Diabetes Care 2014;37(8):2159-67
60. Grimm M, Han J, Weaver C, et al.
Efficacy, safety, and tolerability of exenatide
once weekly in patients with type 2 diabetes
mellitus: an integrated analysis of the
DURATION trials. Postgrad Med 2013;
125(3):47-57
61. Rosenstock J, Forst T, Aronson R, et al.
Efficacy and safety of once-daily lixisenatide
added on to titrated glargine plus oral
agents in type 2 diabetes: getgoal-duo 1
study. Abstract #62-OR. Presented at:
American Diabetes Association, 2012
62. Ferdinand KC, White WB, Calhoun DA,
et al. Effects of the once-weekly glucagon-
like peptide-1 receptor agonist dulaglutide
on ambulatory blood pressure and heart rate
in patients with type 2 diabetes mellitus.
Hypertension 2014. [Epub ahead of print]
63. Robinson LE, Holt TA, Rees K, et al.
Effects of exenatide and liraglutide on heart
rate, blood pressure and body weight:
systematic review and meta-analysis. BMJ
Open 2013;3(1):e001986
64. Chatterjee DJ, Khutoryansky N,
Zdravkovic M, et al. Absence of QTc
prolongation in a thorough QT study with
subcutaneous liraglutide, a once-daily
human GLP-1 analog for treatment of type
2 diabetes. J Clin Pharmacol 2009;49(11):
1353-62
65. Darpo B, Zhou M, Matthews J, et al.
Albiglutide does not prolong QTc interval
in healthy subjects: a thorough ECG study.
Diabetes Ther 2014;5(1):141-53
66. Linnebjerg H, Seger M, Kothare PA, et al.
A thorough QT study to evaluate the effects
of singledose exenatide 10 mug on cardiac
repolarization in healthy subjects. Int J Clin
Pharmacol Ther 2011;49(10):594-604
67. Parks M, Rosebraugh C. Weighing risks
and benefits of liraglutide - the FDA’sreview of a new antidiabetic therapy. N
Engl J Med 2010;362(9):774-7
68. Marso SP, Lindsey JB, Stolker JM, et al.
Cardiovascular safety of liraglutide assessed
in a patient-level pooled analysis of phase 2:
3 liraglutide clinical development studies.
Diab Vasc Dis Res 2011;8(3):237-40
69. Monami M, Dicembrini I, Nardini C, et al.
Effects of glucagon-like peptide-1 receptor
agonists on cardiovascular risk: a meta-
analysis of randomized clinical trials.
Diabetes Obes Metab 2014;16(1):38-47
70. Anderson SL, Trujillo JM. Association of
pancreatitis with glucagon-like peptide-1
agonist use. Ann Pharmacother 2010;44(5):
904-9
71. Singh S, Chang HY, Richards TM, et al.
Glucagon-like peptide 1-based therapies and
risk of hospitalization for acute pancreatitis
in type 2 diabetes mellitus: a population-
based matched case-control study. JAMA
Intern Med 2013;173(7):534-9
72. Garg R, Chen W, Pendergrass M. Acute
pancreatitis in type 2 diabetes treated with
exenatide or sitagliptin: a retrospective
observational pharmacy claims analysis.
Diabetes Care 2010;33(11):2349-54
• This large observational study identified
an increased risk of acute pancreatitis in
diabetic versus non-diabetic patients, but
did not see an association between
exenatide use and pancreatitis.
Review Yabe & Seino
doi: 10.1586/17446651.2014.949672 Expert Rev. Endocrinol. Metab.
Exp
ert R
evie
w o
f E
ndoc
rino
logy
& M
etab
olis
m D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y 18
2.24
9.24
7.14
on
09/0
3/14
For
pers
onal
use
onl
y.
73. Monami M, Dicembrini I, Nardini C, et al.
Glucagon-like peptide-1 receptor agonists
and pancreatitis: a meta-analysis of
randomized clinical trials. Diabetes Res Clin
Pract 2014;103(2):269-75
74. Egan AG, Blind E, Dunder K, et al.
Pancreatic safety of incretin-based drugs –
FDA and EMA assessment. N Engl J Med
2014;370(9):794-7
• This study reported comprehensive
independent evaluations by both the
European and US regulatory bodies that
found that assertions of a causal
relationship between GLP-1 RAs and
pacreatitis or pancreatic cancer were not
consistent with the currently available
data.
75. Bjerre KL, Madsen LW, Andersen S, et al.
Glucagon-like Peptide-1 receptor agonists
activate rodent thyroid C-cells causing
calcitonin release and C-cell proliferation.
Endocrinology 2010;151(4):1473-86
76. Hegedus L, Moses AC, Zdravkovic M, et al.
GLP-1 and calcitonin concentration in
humans: lack of evidence of calcitonin
release from sequential screening in over
5000 subjects with type 2 diabetes or
nondiabetic obese subjects treated with the
human GLP-1 analog, liraglutide. J Clin
Endocrinol Metab 2011;96(3):853-60
77. Elashoff M, Matveyenko AV, Gier B, et al.
Pancreatitis, pancreatic, and thyroid cancer
with glucagon-like peptide-1-based
therapies. Gastroenterology 2011;141(1):
150-6
78. Nauck MA, Friedrich N. Do GLP-1-based
therapies increase cancer risk? Diabetes Care
2013;36(Suppl 2):S245-52
79. Kawata T, Kanamori A, Kubota A, et al. Is
a switch from insulin therapy to liraglutide
possible in Japanese type 2 diabetes mellitus
patients? J Clin Med Res 2014;6(2):138-44
80. Kim YG, Hahn S, Oh TJ, et al. Differences
in the HbA1c-lowering efficacy of glucagon-
like peptide-1 analogues between Asians and
non-Asians: a systematic review and meta-
analysis. Diabetes Obes Metab 2014. [Epub
ahead of print]
81. Seino Y, Takami A, Boka G, et al.
Pharmacodynamics of the glucagon-like
peptide-1 receptor agonist lixisenatide in
Japanese and Caucasian patients with type 2
diabetes mellitus poorly controlled on
sulphonylureas with/without metformin.
Diabetes Obes Metab 2014;16(8):739-47
82. Fukushima M, Suzuki H, Seino Y. Insulin
secretion capacity in the development from
normal glucose tolerance to type 2 diabetes.
Diabetes Res Clin Pract 2004;66(Suppl 1):
S37-43
83. Yabe D, Watanabe K, Sugawara K, et al.
Comparison of incretin immunoassays with
or without plasma extraction: incretin
secretion in Japanese patients with type 2
diabetes. J Diabetes Investig 2012;3(1):70-9
84. Yabe D, Kuroe A, Watanabe K, et al. Little
enhancement of meal-induced GLP-1
secretion in Japanese: comparison of type 2
diabetes and healthy controls. J Diabetes
Investig 2010;1(1-2):56-9
85. Meier JJ, Vilsboll T, Donsmark M, et al.
Greater glycaemic control is achieved with
the once-daily human GLP-1 analogue
liraglutide vs comparators across the
continuum of estimated beta cell mass.
Diabetologia 2011;54(Suppl 1):1-542
• A study that demonstrated the potential
for GLP-1 RAs in aiding glycemic
control, even in patients with advanced
diabetes (low b-cell mass).
86. Usui R, Yabe D, Kuwata H, et al.
Retrospective analysis of safety and efficacy
of insulin-to-liraglutide switch in Japanese
type 2 diabetes: a caution against
inappropriate use in patients with reduced
I2-cell function. J Diabetes Invest 2001;4(6):
585-94
87. Anichini R, Cosimi S, Di CA, et al. Gender
difference in response predictors after 1-year
exenatide therapy twice daily in type 2
diabetic patients: a real world experience.
Diabetes Metab Syndr Obes 2013;6:123-9
88. Yabe D, Seino Y. Incretin actions beyond
the pancreas: lessons from knockout mice.
Curr Opin Pharmacol 2013;13(6):946-53
89. Fujita H, Morii T, Fujishima H, et al. The
protective roles of GLP-1R signaling in
diabetic nephropathy: possible mechanism
and therapeutic potential. Kidney Int 2014;
85(3):579-89
• This study in a mouse model identified a
protective role for GLP-1 against
oxidative stress in the kidney.
90. Seino Y, Yabe D. GIP and GLP-1: incretin
actions beyond the pancreas. J Diabetes
Investig 2013;4(2):108-30
91. Buse JB, Bergenstal RM, Glass LC, et al.
Use of twice-daily exenatide in Basal
insulin-treated patients with type 2 diabetes:
a randomized, controlled trial. Ann Intern
Med 2011;154(2):103-12
92. DeVries JH, Bain SC, Rodbard HW, et al.
Sequential intensification of metformin
treatment in type 2 diabetes with liraglutide
followed by randomized addition of basal
insulin prompted by A1C targets. Diabetes
Care 2012;35(7):1446-54
93. Riddle MC, Aronson R, Home P, et al.
Adding once-daily lixisenatide for type 2
diabetes inadequately controlled by
established basal insulin: a 24-week,
randomized, placebo-controlled comparison
(GetGoal-L). Diabetes Care 2013;36(9):
2489-96
94. Vilsboll T, Christensen M, Junker AE, et al.
Effects of glucagon-like peptide-1 receptor
agonists on weight loss: systematic review
and meta-analyses of randomised controlled
trials. BMJ 2012;344:d7771
95. Monami M, Dicembrini I, Marchionni N,
et al. Effects of glucagon-like peptide-1
receptor agonists on body weight: a meta-
analysis. Exp Diabetes Res
2012;2012:672658
96. Flint A, Raben A, Astrup A, Holst JJ.
Glucagon-like peptide 1 promotes satiety
and suppresses energy intake in humans. J
Clin Invest 1998;101(3):515-20
97. Ussher JR, Drucker DJ. Cardiovascular
biology of the incretin system. Endocr Rev
2012;33(2):187-215
98. Nikolaidis LA, Mankad S, Sokos GG, et al.
Effects of glucagon-like peptide-1 in patients
with acute myocardial infarction and left
ventricular dysfunction after successful
reperfusion. Circulation 2004;109(8):962-5
99. Read PA, Khan FZ, Dutka DP.
Cardioprotection against ischaemia induced
by dobutamine stress using glucagon-like
peptide-1 in patients with coronary artery
disease. Heart 2012;98(5):408-13
100. Lonborg J, Kelbaek H, Vejlstrup N, et al.
Exenatide reduces final infarct size in
patients with ST-segment-elevation
myocardial infarction and short-duration of
ischemia. Circ Cardiovasc Interv 2012;5(2):
288-95
101. Lonborg J, Vejlstrup N, Kelbaek H, et al.
Exenatide reduces reperfusion injury in
patients with ST-segment elevation
myocardial infarction. Eur Heart J 2012;
33(12):1491-9
102. Wang B, Zhong J, Lin H, et al. Blood
pressure-lowering effects of GLP-1 receptor
agonists exenatide and liraglutide: a meta-
analysis of clinical trials. Diabetes Obes
Metab 2013;15(8):737-49
103. Fonseca VA, Devries JH, Henry RR, et al.
Reductions in systolic blood pressure with
liraglutide in patients with type 2 diabetes:
insights from a patient-level pooled
analysis of six randomized clinical trials. J
Diabetes Complications 2014;28(3):
399-405
Defining the role of GLP-1 RAs for individualized treatment of type 2 diabetes Review
informahealthcare.com doi: 10.1586/17446651.2014.949672
Exp
ert R
evie
w o
f E
ndoc
rino
logy
& M
etab
olis
m D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y 18
2.24
9.24
7.14
on
09/0
3/14
For
pers
onal
use
onl
y.
104. Irace C, De LS, Shehaj E, et al. Exenatide
improves endothelial function assessed by
flow mediated dilation technique in subjects
with type 2 diabetes: results from an
observational research. Diab Vasc Dis Res
2013;10(1):72-7
105. Kim M, Platt MJ, Shibasaki T, et al. GLP-
1 receptor activation and Epac2 link atrial
natriuretic peptide secretion to control of
blood pressure. Nat Med 2013;19(5):
567-75
• This study identified a novel mechanism
by which GLP-1 plays a role in
regulation of blood pressure.
106. Meier JJ, Gethmann A, Gotze O, et al.
Glucagon-like peptide 1 abolishes the
postprandial rise in triglyceride
concentrations and lowers levels of non-
esterified fatty acids in humans.
Diabetologia 2006;49(3):452-8
107. Schwartz EA, Koska J, Mullin MP, et al.
Exenatide suppresses postprandial elevations
in lipids and lipoproteins in individuals
with impaired glucose tolerance and recent
onset type 2 diabetes mellitus.
Atherosclerosis 2010;212(1):217-22
108. Arnolds S, Dellweg S, Clair J, et al. Further
improvement in postprandial glucose
control with addition of exenatide or
sitagliptin to combination therapy with
insulin glargine and metformin: a proof-of-
concept study. Diabetes Care 2010;33(7):
1509-15
109. Leahy JL. Insulin therapy in type 2 diabetes
mellitus. Endocrinol Metab Clin North Am
2012;41(1):119-44
110. Nayak UA, Govindan J, Baskar V, et al.
Exenatide therapy in insulin-treated type 2
diabetes and obesity. QJM 2010;103(9):
687-94
111. Owens DR, Luzio SD, Sert-Langeron C,
Riddle MC. Effects of initiation and
titration of a single pre-prandial dose of
insulin glulisine while continuing titrated
insulin glargine in type 2 diabetes: a
6-month ‘proof-of-concept’ study. Diabetes
Obes Metab 2011;13(11):1020-7
112. Riddle MC, Aronson R, Home P, et al.
Adding once-daily lixisenatide for type 2
diabetes inadequately controlled by
established basal insulin: a 24-week,
randomized, placebo-controlled comparison
(GetGoal-L). Diabetes Care 2013;36(9):
2489-96
113. Riddle MC, Forst T, Aronson R, et al.
Adding once-daily lixisenatide for type 2
diabetes inadequately controlled with newly
initiated and continuously titrated basal
insulin glargine: a 24-Week, randomized,
placebo-controlled study (GetGoal-Duo 1).
Diabetes Care 2013;36(9):2497-503
114. Tobin GS, Cavaghan MK, Hoogwerf BJ,
McGill JB. Addition of exenatide twice
daily to basal insulin for the treatment of
type 2 diabetes: clinical studies and practical
approaches to therapy. Int J Clin Pract
2012;66(12):1147-57
115. Gross JL, Kramer CK, Leitao CB, et al.
Effect of antihyperglycemic agents added to
metformin and a sulfonylurea on glycemic
control and weight gain in type 2 diabetes:
a network meta-analysis. Ann Intern Med
2011;154(10):672-9
116. Mathieu C, Rodbard HW, Cariou B, et al.
A comparison of adding liraglutide versus a
single daily dose of insulin aspart to insulin
degludec in subjects with type 2 diabetes
(BEGIN: VICTOZA ADD-ON). Diabetes
Obes Metab 2014;16(7):636-44
117. Wu D, Li L, Liu C. Efficacy and safety of
dipeptidyl peptidase-4 inhibitors and
metformin as initial combination therapy
and as monotherapy in patients with type 2
diabetes mellitus: a meta-analysis. Diabetes
Obes Metab 2013;16(1):30-7
118. Diamant M, Van GL, Stranks S, et al.
Once weekly exenatide compared with
insulin glargine titrated to target in patients
with type 2 diabetes (DURATION-3): an
open-label randomised trial. Lancet 2010;
375(9733):2234-43
119. Blevins T, Pullman J, Malloy J, et al.
DURATION-5: exenatide once weekly
resulted in greater improvements in
glycemic control compared with exenatide
twice daily in patients with type 2 diabetes.
J Clin Endocrinol Metab 2011;96(5):
1301-10
120. Umpierrez G, Tofe Povedano S,
Perez Manghi F, et al. Efficacy and Safety
of Dulaglutide Monotherapy Versus
Metformin in Type 2 Diabetes in a
Randomized Controlled Trial (AWARD-3).
Diabetes Care 2014;37(8):2168-76
Review Yabe & Seino
doi: 10.1586/17446651.2014.949672 Expert Rev. Endocrinol. Metab.
Exp
ert R
evie
w o
f E
ndoc
rino
logy
& M
etab
olis
m D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y 18
2.24
9.24
7.14
on
09/0
3/14
For
pers
onal
use
onl
y.